Who should profit from cutting-edge academic research: the scientists or the institution that funds them? Both, in a new biotech company launched by one of Sweden’s leading researchers.

In a landmark deal for Asia, the first takeover of European biotech firms by a counterpart in Singapore has been finalised.

Sweden is ranked number one among 31 European nations for its spending on R&D - but it is still looking for its first home-grown biotechnology product.

The competition to lure biotech investors and know-how is heating up in US states - and so are the legal battles between over fair and unfair incentives.

Philippe Pouletty is a man with a mission - to make France synonymous with biotechnology. He has his work cut out...

The annual growth of biotech cultivation grew last year at its slowest pace since 1996, when biotech crops were first commercialised, according to a report by the International Service for the Acquisition of Agri-Biotech Applications, a non-profit group that advocates the use of bio-crops.

It has been six years since a French biotech company made a stock market debut – and now two, BioAlliance and ExonHit, are doing so. Is the European market reawakening?

A spin-out from Sheffield that uses stem cells to help with conventional drug discovery is looking for investment to continue pre-clinical research on therapeutic applications and business development activities.

Imperial College London's technology commercialisation company is betting on a spin-out company, deltaDOT, to speed detection and decrease costs of finding new proteins for drug discovery.

A new life-science fund said it raised €240.3 million – and promptly announced its first two investments.